Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Gilead's Coronavirus Drug Being Stocked by the US Government
by Zacks Equity Research
Gilead's (GILD) coronavirus drug, remdesivir, is being stocked by the Trump administration through September.
Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.
Gilead Prices Coronavirus Drug Remdesivir at $390 Per Vial
by Zacks Equity Research
Gilead (GILD) prices experimental coronavirus drug, remdesivir, at $390 per vial.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $74.56, marking a -0.01% move from the previous day.
GILD vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?
The Final Chapter of Chesapeake Energy Story?
by Mark Vickery
Finding difficulties in dealing with its now $10 billion in debt, fracking pioneer Chesapeake Energy (CHK) has announced it is filing for Chapter 11 bankruptcy protection.
Chesapeake Energy Files Chapter 11
by Zacks Equity Research
Chesapeake Energy Files Chapter 11
Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation
by Zacks Equity Research
Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.
3 Stocks to Buy as Companies Speed Up Vaccine Production
by Ritujay Ghosh
Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.
Invest in the Future With Megatrend ETFs
by Neena Mishra
These ETFs invest in fast growing areas like robotics and AI, genomics and cybersecurity.
Alexion's (ALXN) SC Ultomiris Meets Primary Goal in Phase III
by Zacks Equity Research
Alexion's (ALXN) subcutaneous formulation of Ultomiris meets primary objective in a late-stage study.
Gilead to Buy 49.9% Stake in Private Biotech for $275M
by Zacks Equity Research
Gilead (GILD) to purchase 49.9% equity interest in privately-held Pionyr Immunotherapeutics. The company can later also exercise an option to acquire the rest of Pionyr.
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $75.05 in the latest trading session, marking a -0.82% move from the prior day.
Gilead to Start Studies for an Inhaled Version of Remdesivir
by Zacks Equity Research
Gilead (GILD) announces plans to start studies for an inhaled version of the experimental candidate, remdesivir, in August.
Novartis Discontinues HCQ Study Due to Enrollment Challenges
by Zacks Equity Research
Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.
Regeneron Gets FDA Nod for Dupixent 300 Mg Pre-Filled Pen
by Zacks Equity Research
Regeneron (REGN) wins FDA approval for a 300-mg, single-dose, pre-filled pen for asthma drug, Dupixent.
Bet on These 5 High Earnings Yield Stocks to Book Profits
by Zacks Equity Research
Earnings yield has an edge over P/E ratio as it can be used to compare a stock with not just other stocks but also with fixed income securities.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $74.62, moving +0.88% from the previous trading session.
Oxford Discovers COVID-19 Treatment, Plus Record Retail Sales
by Mark Vickery
Dexamethasone is a generic anti-inflammatory drug already prescribed by physicians more than a million times per year, for various conditions.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus
by Kinjel Shah
The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.
3 Big Biotechs Poised for Growth Amid Coronavirus Pandemic
by Ekta Bagri
We highlight a few leading players from the biotech sector, who are likely to see a good run as the year progresses.
Lilly Begins Phase III Study on Olumiant for Coronavirus
by Zacks Equity Research
Lilly's (LLY) Olumiant is being studied for COVID-19 on the assumption that JAK1 and JAK2 inhibition may reduce cytokine storm, a complication associated with COVID-19.